A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Abroad (travel likely)RecruitingPHASE3
Conditions
Hyperphosphatemia Patients on Hemodialysis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Contact: Study coordinator (Taisho Director Taisho Pharmaceutical Co., Ltd selected site) · shu_chiken@taisho.co.jp · 81-3-3985-1118
Study leads
Taisho Director Taisho Director
Study Director
Taisho Pharmaceutical Co., Ltd.